Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Efficacy And Safety Study Of SU011248 In Combination With Trastuzumab As Treatment For Metastatic Disease In Patients With Breast Cancer

NCT00243503 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00243503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00243503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Efficacy And Safety Study Of SU011248 In Combination With Trastuzumab As Treatment For Metastatic Disease In Patients With Breast Cancer
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
July 31, 2010
Enrollment
60 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms